Last reviewed · How we verify
RSVPreF3 vaccine — Competitive Intelligence Brief
phase 3
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
RSVPreF3 vaccine (RSVPreF3 vaccine) — GlaxoSmithKline. The RSVPreF3 vaccine works by stimulating the body to produce a protective immune response against the respiratory syncytial virus (RSV).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RSVPreF3 vaccine TARGET | RSVPreF3 vaccine | GlaxoSmithKline | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RSVPreF3 vaccine CI watch — RSS
- RSVPreF3 vaccine CI watch — Atom
- RSVPreF3 vaccine CI watch — JSON
- RSVPreF3 vaccine alone — RSS
Cite this brief
Drug Landscape (2026). RSVPreF3 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/rsvpref3-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab